Skip to main content
Signal8

BIOMERICA INC (BMRA)

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

Sector: In Vitro & In Vivo Diagnostic Substances

Industry: Medical - Devices

Biomerica, Inc. logo

Biomerica, Inc.

NASDAQ:BMRAHealthcare
-1.15%$1.72
Mkt Cap$7.91M
Float4.11M
O/S4.6M
Vol
$ Vol
RVOL
Inst Own2.8%
SI0.3%
Earnings
Dilution
Pipeline3 lead-sponsored trials·0 active3 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Observational
    Completed

    Specimen Collection Study for H. Pylori Testing

    -

    Helicobacter Infections

    Enrollment
    98
    Start
    Feb 2017
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT02970110
  • Not applicable
    Completed

    Endpoint Determination Study Protocol

    Food Elimination Diet

    Irritable Bowel Syndrome

    Enrollment
    556
    Start
    Jun 2018
    Primary Completion
    Dec 2021
    Completion
    Dec 2021
    NCT03459482
  • Observational
    Completed

    Specimen Collection Study Protocol

    -

    Focus in on Collecting Paired Specimens for Matrix Equivalency

    Enrollment
    47
    Start
    Jul 2020
    Primary Completion
    May 2021
    Completion
    May 2021
    NCT04468386